Get the latest news and discover our mission and vision. Meet our company speakers and get in touch for press and investor inquiries.
Read the latest of myTomorrows
Clinical trial matchmaker myTomorrows has struck up a partnership with personal health recordkeeper Patients Know Best (PKB) so that UK participants can search for possible trials to join.
myTomorrows and Patients Know Best (PKB) have partnered to enable UK patients with unmet medical needs to conduct more efficient searches for further treatment options.
Romina Dibra MD, expert at healthcare technology company myTomorrows, has shared her insight into the most recent technological advancements in ALS Management and how they aim to enhance early diagnosis, significantly improve quality of life and provide more effective, personalized treatments.
Angela Sarmiento Betancourt, MD. at myTomorrows, shares her insights into current strategies and patient-centric research advancements for the treatment of type 1 diabetes.
With the goal of streamlining industry-wide clinical trial recruitment and improving patient outcomes, myTomorrows unveils its next major AI-powered technological advancement.
Michel van Harten, MD, discusses the importance of accessibility within oncological clinical trials which pave the way for better patient outcomes and accelerate critical cancer treatments.
Designed to streamline clinical trial recruitment, the platform supercharges how physicians search, pre-screen, and refer patients — helping trial sponsors accelerate enrollment, enhance diversity, and optimize operations.
Michel van Harten, MD, discusses how physicians and BioPharma companies and patient advocacy groups can address trust challenges by actively engaging with patient communities to empower them to participate in shaping the future of medicine.
Danny den Hamer, myTomorrows Product Manager discussed the use of AI to improve oncology care and how it can support finding the right clinical trials for patients.
Angela Sarmiento Betancourt MD, Medical Affairs Manager shares her insights on the key red flags of cervical cancer, including some common symptoms and how to spot them early.
Michel van Harten, MD, discusses how by addressing structural barriers and expanding awareness can help boost participation in clinical trials, potentially advance the development and approval of new drugs, and inform accessibility for patients with rare diseases.
Michel van Harten, MD, contributes to the discussion noting the emerging importance of decentralized trial designs, enhanced community engagement and the important role of patient advocacy groups.
In this discussion, Jytte van Huijstee, Director of Clinical Trial Operations at myTomorrows, shares insights on technology’s role in clinical trials, addressing recruitment gaps, and fostering diversity.
The myTomorrows search function now includes the ISRCTN while its platform has added AI eligibility checking for clinical trials.
Drawing on its extensive experience connecting physicians and patients to different treatment options, myTomorrows will address challenges in accessing treatments in development across the growing and diverse APAC market.
The primary goal of the hub is to build an operational foundation that can serve growing markets in the region and help patients.
In this podcast Michel van Harten, MD speaks about creating better information systems for physicians and patients & how shared decision-making can improve drug development and more.
In this article, Michel van Harten MD, discusses the profound consequences that equitable and ethical care can have on patient outcomes.
Kelly Brazzo, founder and CEO of CureLGMD2i Foundation, and Dennis Akkaya, chief Commercial Officer at MyTomorrows, share insights on a new partnership that aims to ease accessibility to drug development trials for patients with LGMD.
myTomorrows CEO Michel van Harten, MD, discusses how Infusing DEI considerations into clinical trial recruitment and enrollment will prove crucial for drug discovery and novel therapies.
CEO of myTomorrows, Michel van Harten M.D. discusses the dangerous implications of medical misinformation, not only for patients but also for healthcare professionals and the wider BioPharma industry.
Under a new partnership, CureLGMD2i will leverage myTomorrows' extensive search engine of ongoing clinical trials to provide patients, caregivers, and healthcare professionals with up-to-date, accessible information about pre-approval treatments that may be relevant to them.
Global health technology company myTomorrows announce a new partnership with Pancreatic Cancer Europe (PCE), a multi-stakeholder platform dedicated to improving care for pancreatic cancer patients.
Pancreatic cancer is notoriously challenging to treat, with a life expectancy of only 6-12 months at the time of diagnosis and a 5-year survival rate of just 10%. This partnership aims to enhance access to clinical trials for people suffering with pancreatic cancer by leveraging myTomorrows’ extensive search engine of ongoing trials.
Marshall Van Beurden, joins myTomorrows as Chief Technology Officer.. Van Beurden previously was the Managing Director for the Amazon Web Services (AWS) development center in the Netherlands and led the Enterprise Engineering team at Miro.
The US FDA recently announced a new initiative aimed at improving access to cancer trials among traditionally underserved populations. myTomorrows CEO Michel van Harten talked to Medtech Insight about how the agency’s plan might reshape the landscape of clinical trials going forward.
Jytte van Huijstee, Director of Clinical Trial Operations at myTomorrows, highlights the shift towards more patient-centric clinical trials. This approach focuses on designing trials that are more considerate of the patient’s needs and convenience, which can enhance patient recruitment and retention.
A new collaboration announced today will help provide brain tumour patients and physicians with accurate information about clinical trials in a bid to improve patient access.
Affecting 80,000 people in England, 12% of brain tumour patients survive beyond five years of diagnosis. myTomorrows has announced a new partnership with a UK-based charity, brainstrust, to support individuals living with brain cancer.
Affecting 80,000 people in England, 12% of brain tumour patients survive beyond five years of diagnosis. myTomorrows has announced a new partnership with a UK-based charity, brainstrust, to support individuals living with brain cancer.
myTomorrows and UK brainstrust plans to increase patient recruitment in brain tumour clinical trials by increasing awareness.
myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with brainstrust, a UK-based charity that helps people living with a brain tumor reach their potential and thrive.
Certain features, commonplace on most e-commerce platforms, can help transform clinical trial search databases.
A non-profit organisation representing the amyotrophic lateral sclerosis (ALS) community in the US is taking a digital approach to connecting patients with suitable clinical trials.
Partnership with leading US-based ALS patient advocacy group furthers myTomorrows' mission of ensuring that patients confronting life-threatening diseases are aware of all possible treatment options
CEO Michel van Harten speaks with Clinical Trial Vanguard about myTomorrows’ innovative use of AI in physician-led clinical trial screening.
"I started myTomorrows in 2012 after losing my father to an aggressive form of lung cancer. As a physician and founder of several biotech companies, I thought I could help him find and access a treatment in development. But I was surprised at how complicated and slow the process was. I decided this had to change, so I dedicated myself to creating an easier and faster way for patients to access treatments in development.
We have grown a lot since then, and our team of experts has helped patients in over 60 countries. But our guiding principle remains the same: We believe every patient should have access to all possible treatment options. We are here for you, so let us know how we can help."
myTomorrows teams up with digital health innovator Congenica, highlighting tech’s role in the future of healthcare.
myTomorrows shares insights on discovering clinical trials for cancer.
myTomorrows’ CEO explores the power of AI for matching patients with the clinical trials right for them
Fierce Biotech shares launch of myTomorrows exciting new AI-backed patient pre-screening tool.
The global Health technology company myTomorrows said it launched the beta version of TrialSearch AI, a first-of-its-kind artificial intelligence tool to broaden physician insights into clinical trials and expanded access programs in the myTomorrows’ curated database.
Our experts have been pulled in to discuss a wide range of topics, from patient-centricity, clinical trials, expanded access, innovation, healthcare technology, artificial intelligence, and many more. Get in touch with them.
myTomorrows aims to break barriers for eligible patients seeking information about clinical trials and we support referrals to trial sites. When patients are not eligible to clinical studies, we can help them and their physicians to further explore and navigate the complexities of expanded access programs.
Our digital platform connects all stakeholders in pre-approval access and supports both clinical trial and expanded access workflows.
myTomorrows operates globally and has offices in Amsterdam and New York City.
We’ve helped
A community of
Trusted by
Media inquiries
mytomorrows@headline.media